CD274 and neoplasm: Atezolizumab is a monoclonal antibody targeting PD-L1 and it enhances immune recognition of tumor cells by preventing PD-L1 from binding to its receptor, restoring T-cell activation and permitting T cells to mount anti-tumor responses [69].